SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934


LYNX THERAPEUTICS, INC.
(Name of Issuer)

Common Stock, Par Value $.01 Per Share
(Title of Class of Securities)

551812308
(CUSIP Number)

May 24, 2001
(Date of Event Which Requires Filing of this Statement)

     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     / /  Rule 13d-1(b)
     /X/  Rule 13d-1(c)
     / /  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<PAGE>

CUSIP No. 693758104

1.  Name of Reporting Person:

     HBK Investments L.P.

2.  Check the Appropriate Box if a Member of a Group:
                                                         (a) /  /

                                                         (b) /X/

3.  SEC Use Only

4.  Citizenship or Place of Organization: Delaware

                     5.  Sole Voting Power: 1,326,168 (1)(2)
Number of
Shares
Beneficially  6.  Shared Voting Power:  0
Owned By
Each
Reporting     7.  Sole Dispositive Power: 1,326,168 (1)(2)
Person
With
                    8.  Shared Dispositive Power:  0

9.    Aggregate Amount Beneficially Owned by Each Reporting Person:

       1,326,168 (1)(2)

10.  Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares:
                                                             /  /

11.  Percent of Class Represented by Amount in Row (9): 9.577%

12.  Type of Reporting Person: PN

- --------------
(1)  Includes 1,061,254 shares of common stock ("Common Stock") owned by HBK Master Fund L.P. ("Master
      Fund") and 264,914 shares of Common Stock issuable upon exercise of Warrants owned by Master Fund
      (collectively, the shares of Common Stock and the shares issuable upon exercise of the Warrants are
      referred to herein as the "Shares").  HBK Investments L.P. ("Investments")has sole voting and dispositive

      power over these shares pursuant to an Investment Management Agreement with Master Fund.
      Accordingly, Master Fund has no beneficial ownership of such shares.

(2)  Investments' power is exercised by its general partner, HBK Partners II L.P., whose general partner is
      HBK Management L.L.C.

<PAGE>

Item 1(a).     Name of Issuer.

    The name of the issuer is Lynx Therapeutics, Inc. the "Issuer").

Item 1(b).    Address of Issuer's Principal Executive Offices.

    The principal executive offices of the Issuer are located at 3832 Bay Center Place, Hayward, CA  94545.

Item 2(a).    Names of Persons Filing.

    Pursuant to Rules 13d-1(f)(1)-(2) of Regulation 13D-G of the General Rules and Regulations under the
Securities Exchange Act of 1934, as amended (the "Act"), this Schedule 13G Statement is hereby filed by HBK
Investments L.P., a Delaware limited partnership (the "Reporting Person"). Additionally, information is included
herein with respect to the following persons (collectively, the "Controlling Persons"): HBK Partners II L.P., a
Delaware limited partnership ("Partners II"), HBK Management L.L.C., a Delaware limited liability company
("Management") and Harlan B. Korenvaes, Kenneth M. Hirsh, Laurence H. Lebowitz, William E. Rose, Richard L.
Booth, David C. Haley and Jamiel A. Akhtar, members of Management, who may control Management
("Managers").  The Reporting Person and the Controlling Persons are sometimes hereinafter collectively referred
to as the "Item 2 Persons."

Item 2(b).    Address of Principal Business Office, or if None, Residence.

    The principal business office for each of the Item 2 Persons is 300 Crescent Court, Suite 700, Dallas, Texas
75201.

Item 2(c).    Citizenship.

     All of the natural persons listed in Item 2(a) are citizens of the United States of America.

Item 2(d).    Title of Class of Securities.

    This statement relates to the Common Stock, par value $.01 per share (the "Stock")of the Issuer.

Item 2(e).    CUSIP Number.

    The CUSIP number of the Shares is 551812308.

Item 3.  Filing Pursuant to Rules 13d-1(b) or 13d-2(b).

     If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person
filing is a:

    (a) / /  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) / /  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) / /  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) / / Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8);

    (e) / /  An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) / /  An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F);

    (g) / /  A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G);

    (h) / /  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);

    (i) / /  A church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) / /  Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

    If this statement is filed pursuant to section 240.13d-1(c), check this box /X/.

Item 4.  Ownership.

    (a) - (b)

    Reporting Persons

     Pursuant to an Investment Management Agreement with Master Fund, Investments may, pursuant to Rule 13d-
3(a), be deemed to be the beneficial owner of the Shares.

    Controlling Persons

    Because of its position as the sole general partner of Investments, Partners II may be deemed to be the beneficial
owner of the Shares.

    Each of (1) Management, as sole general partner of Partners II, and (2) the Managers, as the controlling
persons of Management may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of the
Shares.

    The Persons listed in Item 2(a) expressly declare that the filing of this statement on Schedule 13G shall not
be construed as an admission that they are, for the purpose of Section 13(d) or 13(g) of the Securities and
Exchange Act of 1934, the beneficial owners of any securities covered by this statement.

    (c)

    Reporting Persons

    Pursuant to an Investment Management Agreement with Master Fund, and acting through its general
partner, Partners II, Investments has the sole power to vote or direct the vote and to dispose or to direct the
disposition of the Shares.

    Controlling Persons

    Acting through its general partner, Management, and in its capacity as the general partner of Investments,
Partners II has the sole power to vote or to direct the vote and to dispose or to direct the disposition of the Shares.

    In its capacity as the general partner of Partners II, Management has the sole power to vote or to direct the vote
and to dispose or to direct the disposition of the Shares.

<PAGE>

    Managers

     In their capacity as controlling persons of Management, the Managers have the sole power to vote or to
direct the vote and to dispose or to direct the disposition of the Shares.

Item 5.  Ownership of Five Percent or Less of a Class.

    Not applicable.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Under an Investment Management Agreement with Master Fund, Investments has the sole power to vote
or to direct the vote and to dispose or to direct the disposition of the Shares.

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on
             By the Parent Holding Company.

    Not applicable.

Item 8.  Identification and Classification of Members of the Group.

Not applicable.

Item 9.  Notice of Dissolution of Group.

    Not applicable.

Item 10.  Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in connection with or as a participant in any
transaction having that purpose or effect.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth
in this statement is true, complete and correct.

    DATED:    June 1, 2001

HBK INVESTMENTS L.P.


By:  /s/ Kevin O'Neal
         Kevin O'Neal
         Authorized Signatory (1)

(1)  An Authorization Certificate authorizing Kevin O'Neal to act on behalf of HBK Investments L.P.
was previously filed.